Immunomodulatory function of orally administered thymosin alpha1

Area of Science:

• Immunology
• Biotechnology
• Molecular Biology

Background:

• Thymosin alpha1 (Talpha1) is a peptide hormone with known immunomodulatory properties.
• Yeast expression systems offer a potential platform for producing therapeutic peptides.
• Investigating novel delivery methods for Talpha1 is crucial for its therapeutic application.

Purpose of the Study:

• To evaluate the immunological function of Talpha1 produced by a yeast expression system.
• To determine the efficacy of orally administered Talpha1 in modulating immune responses.
• To assess the impact of Talpha1 on T-cell populations and cytokine production.

Main Methods:

• A Talpha1 yeast expression system was constructed and utilized.
• Balb/c mice, both normal and immunosuppressed with cyclophosphamide, were orally administered Talpha1.
• Flow cytometry and liquid chip assays were employed to measure CD4(+), CD8(+) levels, and cytokine profiles (TNF-alpha, IFN-gamma, IL-2, IL-6, IL-10).

Main Results:

• Oral administration of Talpha1 significantly increased CD8(+) T-cell levels in both normal and immunosuppressed mice.
• In immunosuppressed mice, Talpha1 treatment led to a dose-dependent increase in CD8(+) T-cell populations compared to controls.
• Specific cytokine levels were modulated, indicating a broader immune response.

Conclusions:

• The yeast expression system successfully produced functional Talpha1.
• Orally administered Talpha1, delivered via yeast, exhibits significant immunomodulatory activity.
• This approach holds promise for developing novel Talpha1-based immunotherapies.